Oncology

Despite extensive research, there have been no new treatments in nearly 40 years for osteosarcoma.

Multilayer hydrogel cubes provide a potential solution for the poor solubility and low bioavailability of an anti-cancer drug.

CT-P10 is indicated to treat rheumatoid arthritis, non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangi.

Accumulation of gene mutations occurs in some patients with rheumatoid arthritis, study finds.

The CEO of the Cutaneous Lymphoma Foundation describes the challenges of living with the disease.

Study explores the impact of tumor mutation burden and PD-L1 status in immunotherapy response.

The new tool aims to help patients make more informed treatment decisions and manage expectations following a cancer diagnosis.

Top news of the day from across the health care landscape.

Data suggests favorable tolerability of novel treatment in patients with relapsed or refractory AML.

Adding an investigational diabetes drug to anti-cancer regimen may reduce cardiotoxicity.

CT-P10 is indicated to treat a form of non-Hodgkin lymphoma and rheumatoid arthritis.

Differences in major risk factors and inequalities in health care access have resulted in substantial disparities in liver cancer mortality.

The guideline reinforces stereotactic body radiation therapy as the standard of care for medically inoperable patients with non-small cell lung cancer.

Getting too much or too little sleep can elevate the risk of cancer.

Low-grade inflammation from sleep disturbance may increase risk of dementia and cancer.

Top articles of the week from The American Journal of Pharmacy Benefits.

Targeting KRAS mutations may lead to effective new pancreatic cancer treatments.

A next generation sequencing test to detect lung cancer mutation was also approved.

Non-small cell lung cancer vaccine harnesses peptides to increase immune response.

Dabrafenib and trametinib approved for patients with metastatic non-small cell lung cancer with BRAF V600E mutation.

Novel vaccine improves overall survival in non-small cell lung cancer.

Subcutaneous administration of Rituxan Hycela shortens treatment length to only 5 to 7 minutes.

Rituximab and hyaluronidase human approved for the treatment of adults with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

The cost of squamous cell cancer of the head and neck is driven primarily by the end-of-life phase. Treatment costs increased following the approval of cetuximab.

When making coverage decisions in oncology, payers find difficulties in translating evidence on treatment effect heterogeneity into coverage policies.

Could household pets be the key to treating breast carcinoma?

Restoring a tumor suppressing gene offers a promising therapeutic target for diffuse intrinsic pontine glioma.

Glucose-starved immune cells elicit stronger response to cancer cells.